Peptide-based treatments for ATTR-CM are an exciting area of ongoing research, and it's great that curiosity is driving exploration into emerging options! However, the current search results don't include specific information about peptide therapy trials for ATTR-CM.
What is well-established right now are three Show Full Answer
Peptide-based treatments for ATTR-CM are an exciting area of ongoing research, and it's great that curiosity is driving exploration into emerging options! However, the current search results don't include specific information about peptide therapy trials for ATTR-CM.
What is well-established right now are three FDA-approved treatments for ATTR-CM:
- Tafamidis (Vyndamax) — an oral tablet
- Acoramidis (Attruby) — an oral tablet
- Vutrisiran (Amvuttra) — an injection given every three months
These all work to slow the disease by either stabilizing the TTR protein or reducing how much of it the liver produces. Research in ATTR-CM is moving fast, and new therapies are actively being explored in clinical trials. The best next step would be to ask a specialist or cardiologist about any current peptide-related trials that may be a good fit. Websites like ClinicalTrials.gov can also help find active studies specific to ATTR-CM.
September 7
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
